How to access Xpovio from the UAE, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
An Emirati patient with relapsed or refractory multiple myeloma (in combination with bortezomib and dexamethasone after at least one prior therapy, or with dexamethasone alone after at least four prior therapies including two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody), or with relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy, may receive a prescription for Xpovio (selinexor) from their treating hematologist. Xpovio is FDA-approved in the United States and manufactured by Karyopharm Therapeutics. It is an oral selective inhibitor of nuclear export (SINE) administered by tablet. Local availability of Xpovio in the UAE can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through MoHAP remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Xpovio in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Xpovio is an oral selective inhibitor of nuclear export. Mechanism: a small-molecule inhibitor of exportin 1 (XPO1, also known as CRM1) that blocks nuclear export of tumor suppressor proteins, leading to their accumulation and pro-apoptotic activity. Dosing: indication-specific, typically 100 mg orally once weekly with bortezomib and dexamethasone for myeloma, or 60 mg twice weekly for r/r DLBCL, per FDA labeling. Baseline workup per FDA labeling includes CBC with differential, comprehensive metabolic panel including sodium, baseline weight, and assessment of hydration. Other important warnings include thrombocytopenia, neutropenia, gastrointestinal toxicity including nausea, vomiting, diarrhea, anorexia, and weight loss, hyponatremia, serious infections, neurological toxicity, embryo-fetal toxicity, and cataract. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Xpovio legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient and personal-use import framework, coordinated through an Emirati-licensed treating facility's pharmacy. The UAE has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The MoHAP named-patient route allows an Emirati-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the indication, prior therapies, and rationale for Xpovio.
- Baseline screening. CBC with differential, comprehensive metabolic panel including sodium, baseline weight, and hydration assessment are confirmed and documented.
- MoHAP named-patient application. Your hematologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Karyopharm Therapeutics' authorised distribution under DSCSA chain-of-custody.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy with the supportive-care plan in place.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis (r/r MM with prior-line history, or r/r DLBCL after at least two prior lines), prior therapies, and Xpovio as the indicated next step
- Verification of their UAE medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (indication-specific, per FDA labeling)
- A monitoring plan covering CBC, sodium, weight, hydration, and supportive antiemetic and nutritional plan
Reserve Meds provides a physician documentation kit tailored for SINE-class therapies, including the templates MoHAP reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the cycle schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Xpovio specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoHAP review, including SINE-class templates.
- Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed UAE pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at the UAE tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Some UAE private insurers and CCHI-aligned plans reimburse named-patient imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
How is the GI toxicity managed? The Xpovio prescribing information includes specific supportive-care recommendations: prophylactic antiemetics with a 5-HT3 antagonist, dose modifications for nausea and weight loss, and aggressive management of hydration and nutrition. Your hematologist coordinates this supportive-care plan with the dispensing pharmacy and clinical team.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major UAE tertiary centers (Cleveland Clinic Abu Dhabi, Tawam Hospital Al Ain, American Hospital Dubai, and Mediclinic City Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoHAP reviewers commonly ask for.
Next step
For Xpovio coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Xpovio in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Xpovio for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Xpovio in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Xpovio. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Xpovio in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Xpovio to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Xpovio to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Xpovio in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Xpovio in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.